Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Endocrinology
•
Thyroid Disorders
In which specific scenarios would you consider transitioning from oral to intravenous thyroid hormone replacement in the outpatient setting?
Related Questions
Would you recommend pharmacologic treatment with levothyroxine for a patient with subclinical hypothyroidism and CAD s/p stent placement even if the TSH is less than 10mIU/L, given a described association with reduced risk for major adverse cardiovascular events with treatment?
How do you counsel breastfeeding women on their limitations post radioactive iodine ablation for thyroid cancer treatment?
Can carbamazepine make thyroid function test results look spuriously abnormal?
How long do you recommend waiting to repeat an ultrasound in patients with cytologically benign thyroid nodules and very low to intermediate suspicion ultrasound patterns?
Is there a role for adding methotrexate to methimazole in the treatment of Graves' disease?
How do you approach the use of supraphysiologic T4 doses in patients with intermediate- and high-risk differentiated thyroid cancer, considering that elevated FT4 levels have not been linked to progression-free survival in recent clinical data?
For patients on desiccated bovine thyroid hormone therapy, how do you approach transitioning to synthetic thyroid hormone derivatives?
Do you recommend low dose RAI ablation for low risk papillary thyroid cancer with lymphatic invasion alone (no angio-invasion or known nodal involvement)?
Statistically speaking, approximately what percentage of thyroid nodule FNA biopsies are Bethesda category 1 (= nondiagnostic or unsatisfactory), and what percentage are indeterminate (Bethesda category 3 and 4)?
Do you recommend completion thyroidectomy and RAIT in patients found to have unifocal minimally invasive follicular variant of papillary carcinoma on pathology after thyroid lobectomy?
